The Bull Rankings scorecard — our quality-growth score is 40.1 / 100, built from three pillars scored 0–100: Quality 52, Growth 39, Value 32 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 34% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Entegris is a solid business whose valuation runs well ahead of its current growth. Our model gives it a 40.1/100 score, with Quality 52 topping the chart and Value 32 lagging. The Quality pillar is the strongest, resting on a 9.2 % profit margin and a 7.4 % ROE. The price, at $140.37, is already pricing in a 34 %/yr free‑cash‑flow growth (in year one, slowing to 3% a year by year ten)—far above the 3.2 % FY YoY revenue growth reported. That gap signals the market is betting on a rapid acceleration that has yet to materialize. If the company can lift revenue growth to the mid‑teens, the current price would be easier to justify; if it stalls, the upside evaporates.
What the business actually is
Entegris delivers the invisible backbone of every advanced chip. In its Materials Solutions (MS) arm it sells chemical vapor and atomic layer deposition materials, chemical mechanical planarization slurries and pads, ion‑implantation specialty gases, and formulated etch and clean materials. The Advanced Purity Solutions (APS) segment supplies filtration, purification, and contamination‑control systems that keep wafers pristine. Customers are the world’s leading semiconductor fabs in North America, Taiwan, South Korea, Japan, China, Europe, and Southeast Asia. The MS line, with its high‑margin specialty gases, is the primary revenue driver, while APS anchors the business with recurring service contracts.
Why it can (or can't) keep compounding
The moat is built on technological lock‑in and scale. The MS products require precision chemistry that is hard to replicate; the APS systems are integrated into fab flows and generate long‑term maintenance revenue. These factors keep competitors—even large equipment makers—at arm’s length. The profit margin of 9.2 % reflects the premium pricing of these niche materials, while an ROE of 7.4 % shows only modest returns on capital. The company’s debt‑to‑equity of 0.86 keeps leverage manageable, allowing reinvestment into R&D without diluting shareholders. The business generates cash flow that can be plowed back into growth.
The valuation question
At $140.37 the P/E of 69.8 is high, and the reverse‑DCF tells the same story: the price implies free cash flow growing about 34 % next year. The current 3.2 % revenue growth is modest; even if the company doubles that pace, the price would still look demanding. Conversely, if revenue growth stalls, the high multiple becomes a liability. The PEG of 1.25 says analysts expect a strong earnings rebound, and the reverse‑DCF demands a fast cash‑flow trajectory too. The valuation is therefore a bet on acceleration rather than a discount.
The bear case
The weakest pillar—Value 32—is the red flag. A low value score indicates the stock is expensive against peers. The high P/E of 69.8 coupled with a PEG of 1.25 shows that investors are already pricing in significant growth. If the semiconductor cycle softens and fabs cut back on new equipment, Entegris could see a revenue slowdown. A single quarter of negative free‑cash‑flow would confirm that the company cannot sustain its current capital expenditures, and the debt‑to‑equity of 0.86 would become a burden rather than a lever. Such a scenario would erode the high quality narrative and force a sharp re‑rating.
What would change our mind
- Revenue growth falling below 2 % YoY would invalidate the 34 % free‑cash‑flow assumption and argue for a much lower multiple.
- Profit margin dipping below 8 % would signal cost pressure and erode the moat that justifies the premium.
- Debt‑to‑equity rising above 1.2 would raise leverage concerns, limiting future investment and diluting shareholder value.
If any of these thresholds are breached, the current thesis collapses, and the stock would need to be re‑evaluated as a speculative or value opportunity rather than a high‑quality compounder.